Mesoblast Limited
MESO
$16.14
-$0.25-1.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 599.21% | 711.76% | 1,053.16% | 613.64% | 191.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 599.21% | 711.76% | 1,053.16% | 613.64% | 191.39% |
| Cost of Revenue | 36.39% | 576.30% | 35,717.40% | 2,576.54% | 497.17% |
| Gross Profit | 23,064.92% | 127.84% | -116.66% | -115.80% | -114.19% |
| SG&A Expenses | 45.89% | 51.35% | 58.17% | 57.81% | 57.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -105.57% | -431.33% | -1,171.96% | -266.60% | 153.96% |
| Total Operating Expenses | 115.34% | 124.80% | 138.33% | 78.21% | 24.51% |
| Operating Income | 17.93% | -7.05% | -37.53% | -21.64% | -7.55% |
| Income Before Tax | 44.13% | 26.51% | 9.13% | -2.22% | -15.50% |
| Income Tax Expenses | 85.76% | 159.60% | 357.72% | 1,413.24% | 272.77% |
| Earnings from Continuing Operations | 43.71% | 26.09% | 8.69% | -2.72% | -16.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.71% | 26.09% | 8.69% | -2.72% | -16.13% |
| EBIT | 17.93% | -7.05% | -37.53% | -21.64% | -7.55% |
| EBITDA | 22.65% | -1.44% | -29.94% | -15.93% | -3.59% |
| EPS Basic | 47.52% | 33.33% | 20.35% | 12.11% | 3.42% |
| Normalized Basic EPS | 25.66% | 18.41% | 11.55% | 10.04% | 8.50% |
| EPS Diluted | 47.28% | 33.11% | 20.13% | 12.00% | 3.42% |
| Normalized Diluted EPS | 25.66% | 18.41% | 11.55% | 10.04% | 8.50% |
| Average Basic Shares Outstanding | 7.21% | 10.72% | 14.51% | 18.21% | 22.41% |
| Average Diluted Shares Outstanding | 7.21% | 10.72% | 14.51% | 18.21% | 22.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |